

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA

CRITICAL CARE DIAGNOSTICS, INC., )  
dba CRITICAL CARE DIAGNOSTICS, )  
Plaintiff, )  
v. )  
AMERICAN ASSOCIATION FOR )  
CLINICAL CHEMISTRY, INC., *et al.*, )  
Defendants. )  
\_\_\_\_\_ )

Civil No. 13cv1308 L (MDD)  
**ORDER GRANTING RAFAI'S  
MOTION TO STRIKE [doc. #30] and  
GRANTING AACC'S AMENDED  
MOTION TO STRIKE [doc. #37]**

Defendants Nader Rifai ("Rifai"), and American Association for Clinical Chemistry, Inc. ("AACC") each move to strike plaintiff's complaint under California Code of Civil Procedure § 425.16, known as the Anti-SLAPP<sup>1</sup> statute. The motions have been fully briefed and are considered without oral argument.

**A. BACKGROUND**

This action concerns a peer-reviewed scientific research article concerning heart disease entitled "Soluble ST2 Is Associated with All-Cause and Cardiovascular Mortality in a Population-Based Cohort: The Dallas Heart Study" ("the Article"). The Article was published by the American Association for Clinical Chemistry ("AACC") in its peer-reviewed scientific

<sup>1</sup> "SLAPP" stands for Strategic Lawsuit Against Public Participation.

1 journal, CLINICAL CHEMISTRY (“Journal”), which reported on the defendant authors’  
2 research regarding ST2 in asymptomatic patients. The article was published on AACC’s website  
3 in December 2012, and in its March 2013 print edition. The AACC is an international  
4 scientific/medical society of clinical laboratory professionals, physicians, research scientists and  
5 other individuals involved with clinical chemistry and related disciplines. Defendant Nader  
6 Rifai, Ph.D., is the Editor-in-Chief of CLINICAL CHEMISTRY (“Journal”). As a peer-reviewed  
7 journal, independent professionals, namely scientists and scholars, review the journal’s articles  
8 and research prior to publication. Comp., ¶ 16. Defendants Lu Q. Chen, James A. De Lemos,  
9 Sandeep R. Das, Colby R. Ayers and Anand Rohatgi (“Author Defendants”)<sup>2</sup> are the credited  
10 authors of the Article. Comp., ¶¶ 4-8.

11 Plaintiff Critical Care Diagnostics, Inc. is a biomarker<sup>3</sup> company that focuses on  
12 cardiovascular diseases. It holds patent rights to an assay, Presage ® ST2 Assay, which the FDA  
13 approved for application to patients already diagnosed with and experiencing existing heart  
14 problems. ST2 can be a significant predictor of mortality due to cardiovascular disease in such a  
15 population. The Article at issue purports to describe one such test to measure ST2 – the Alere  
16 ST2 assay, and not the Presage ® ST2 Assay. However, the Article is not an evaluation of  
17 commercially available assays, approved FDA assays, or plaintiff or plaintiff’s product. Instead,  
18 the Article focuses on ST2 research using an assay other than plaintiff’s assay to be applied to  
19 the general asymptomatic population. The Alere ST2 assay is not FDA approved at this time.

20 The Journal has a regular policy and procedure for the review of articles it publishes. As  
21 Editor-in-Chief, defendant Rifai, reviews manuscripts for subject matter only. Then an associate  
22 editor reviews the manuscript and assigns it to two peer reviewers. After further review by the  
23 Deputy Editor, James C. Boyd, M.D., a manuscript is accepted for publication. Dr. Boyd’s  
24

---

25 <sup>2</sup> The Author defendants have filed a motion to dismiss for lack of personal  
26 jurisdiction and for failure to state a claim. They have also filed a motion to strike under Texas  
27 Civil Practice & Remedies Code § 27.001. [doc. #38] These motions will be addressed in a  
subsequent Order.

28 <sup>3</sup> “Biomarker” refers to a biologic feature that can be used to measure the presence  
or progress of disease or the effects of treatment.

1 approval is the final approval required for publication.

2 Plaintiff contends that the Article contains false statements that were known to Rifai and  
3 the AACC publisher defendant because of prior studies and articles. Specifically, plaintiff points  
4 to what it alleges are three factually untrue statements:

5 – The Article states “to our knowledge, no prior study has evaluated sST2 as a cardiac  
6 biomarker in the general population.” (Article at 537.) Plaintiff contend that a proper literature  
7 search would have revealed that two prior articles had performed such an evaluation.

8 – The Article states that plaintiff’s Presage Assay was less sensitive at detecting ST2 than  
9 the Alere assay which was used in the study. (Article at 537.) Plaintiff asserts that the Presage  
10 Assay measures ST2 in 100% of the population and therefore, is more sensitive than the Alere  
11 assay.

12 – The Article states that “[t]he development of more sensitive assays is needed to fully  
13 explore the potential role of this biomarker for population screening.” (Article at 544.) Plaintiff  
14 states that the “Presage Assay was a ‘more sensitive assay’ which had already been developed  
15 and utilized in exploring the potential role of the sST2 biomarker. (Opp. at 7-8. (emphasis in  
16 original.))

17 According to plaintiff, defendants “deliberately chose to make false statements which cast  
18 the Preage Assay in a negative light.” *Id.* at 9. Also, plaintiff asserts that the publisher defendant  
19 allowed the author defendants to misstate their financial relationship with Alere.

20 Finally, plaintiff contends that after the print publication of the Article, it suffered at least  
21 one specific lost distribution deal with the SMS Gruppen Danmark company in Denmark, which  
22 was to be the Danish distributor of the Presage Assay. (Geliebter Decl. ¶8.)

## 23 **B. LEGAL STANDARD**

24 California Civil Procedure Code §425.16 was enacted “to provide for the early dismissal  
25 of unmeritorious claims filed to interfere with the valid exercise of the constitutional rights of  
26 freedom of speech and petition for the redress of grievances.” *Club Members for an Honest*  
27 *Election v. Sierra Club*, 45 Cal.4th 309, 315 (2008). Section 425.16 thus allows a court to strike  
28 any cause of action that arises from the defendant's exercise of his or her constitutionally

1 protected free speech rights or petition for redress of grievances. §425.16 (b)(1); *see also Flatley*  
2 *v. Mauro*, 39 Cal.4th 299, 311–312 (2006). In ruling on a special motion to strike brought under  
3 § 425.16, the trial court must engage in a two-step process that involves shifting burdens. First,  
4 the court must determine whether defendant has made a threshold showing that the challenged  
5 cause of action “arises from” a protected activity. Second, if the defendant makes this showing,  
6 the trial court must determine whether the plaintiff has established a probability of prevailing on  
7 the claim. *Jarrow Formulas, Inc. v. LaMarche*, 31 Cal.4th 728, 733 (2003). “‘Reasonable  
8 probability’ in the anti-SLAPP statute has a specialized meaning” and “requires only a  
9 ‘minimum level of legal sufficiency and triability.’” *Mindys Cosmetics, Inc. v. Dakar*, 611 F.3d  
10 590, 598 (9th Cir. 2010) (quoting *Linder v. Thrifty Oil Co.*, 23 Cal.4th 429, 438 n. 5 (2000)). In  
11 order to satisfy this burden, the plaintiff “must demonstrate that the complaint is both legally  
12 sufficient and supported by a sufficient prima facie showing of facts to sustain a favorable  
13 judgment if the evidence submitted by the plaintiff is credited.” *Wilson v. Parker, Covert &*  
14 *Chidester*, 28 Cal.4th 811, 821(2002); *see also Metabolife Int'l, Inc. v. Wornick*, 264 F.3d 832,  
15 840 (9th Cir. 2001). “‘The plaintiff’s showing of facts must consist of evidence that would be  
16 admissible at trial.’” *Stewart v. Rolling Stone LLC*, 181 Cal. App.4th 664, 679 (2010).  
17 “[D]eclarations that lack foundation or personal knowledge, or that are argumentative,  
18 speculative, impermissible opinion, hearsay, or conclusory are to be disregarded.” *Gilbert v.*  
19 *Sykes*, 147 Cal. App.4th 13, 26 (2007).

20 Each challenged basis for liability must be examined individually to determine if the  
21 plaintiff has demonstrated a probability of prevailing, and if the plaintiff has failed to do so, then  
22 only that basis must be stricken from the plaintiff’s pleading. *Navellier v. Sletten*, 29 Cal.4th 82,  
23 89 (2002).

### 24 **C. DISCUSSION**

25 As noted above, both Dr. Rafai and the AACC move to strike plaintiff’s entire complaint  
26 under the anti-SLAPP statute. Plaintiff has included causes of action for libel per se, libel per  
27 quod, trade libel, and violation of California Business & Professions Code §17200, *et seq.*

28 ///

1           **1.     Arising from Protected Activity**

2           Section 425.16(e) specifies the four categories of protected speech or petitioning activity.

3 Relevant in this action are categories 3 and 4:

4                   (e) As used in this section, “act in furtherance of a person's right of petition or free  
5 speech under the United States or California Constitution in connection with a  
6 public issue” includes: . . .

7                   (3) any written or oral statement or writing made in a place open to the public or a  
8 public forum in connection with an issue of public interest, or (4) any other  
9 conduct in furtherance of the exercise of the constitutional right of petition or the  
10 constitutional right of free speech in connection with a public issue or an issue of  
11 public interest.

12           **a.     Public Forum**

13           In order for defendants to fall within 425.16(e)(3), they must demonstrate that the written  
14 statements found in the Article were made in a “place open to the public or a public forum.”  
15 California case law repeatedly notes that the “public forum” term in the statute is entitled to a  
16 broad reading. *See Nygard*, 159 Cal. App.4th at 1038, citing *Damon v. Ocean Hills Journalism*  
17 *Club*, 85 Cal. App. 4<sup>th</sup> 468, 476-77 (2000).

18           The Article was made available to the public on the AACC’s website. Plaintiff’s  
19 suggestion that interactivity is required for a public forum is not supported by case law. Instead,  
20 the California Supreme Court has held that “public access, not the right to public comment, is  
21 the hallmark of a public forum.” *Nygaard, Inc. v. Uusi-Kerttula*, 159 Cal. App.4th 1027, 1039  
22 (2008) citing *Barrett v. Resenthal*, 40 Cal.4th 33, 41 fn.4 (2006). “The Internet is a classic public  
23 forum which permits an exchange of views in public about everything . . . .” *Chaker v. Mateo*,  
24 209 Cal. App.4th 1138, 1146 (2012).

25           Because the Article is available on AACC’s website, defendants have met their burden of  
26 showing that the publication of the Article was made in a public forum.

27           **b.     In Connection with an Issue of Public Interest**

28           Like “public forum”, the term “issue of public interest” is construed broadly in the  
anti-SLAPP context. *Hecimovich v. Encinal School Parent Teacher Organization*, 203 Cal.  
App.4th 450, 464 (2012). An issue of public interest is “any issue in which the public is  
interested.” *Nygrd*, 159 Cal. App.4th at 1042. The issue does not need to be “significant” to be

1 covered by the anti-SLAPP statute. *Id.* Statements may be connected to an issue of public  
2 interest if they concern a person or entity in the public eye, a topic of widespread public interest,  
3 or conduct that could directly affect a large number of people beyond the direct participants.  
4 *Rivero v. American Federation of State, County and Municipal Employees, AFL-CIO* 105, Cal.  
5 App.4th 913, 924 (2003).

6 Defendants argue that because the Article addresses research findings concerning ST2,  
7 which may be a predictor of mortality due to cardiovascular disease in asymptomatic patients,  
8 the public interest prong is met. As a result, because heart disease is the leading cause of death  
9 for both men and women, the Article is of public interest under either §425.16(e)(3) or (e)(4).

10 Plaintiff argues, however, that the alleged defamatory statements in the Article did not  
11 arise from constitutionally-protected activity. In so arguing, plaintiff contends that the issue must  
12 be of concern to a substantial number of people and not just to a relatively small, specific  
13 audience. *Weinberg*, 110 Cal. App. 4<sup>th</sup> at 1132, In other words, plaintiff contends that the Article  
14 does not concern a matter of widespread public interest, but instead is of interest to a narrow  
15 group of medical or laboratory professionals.” (Opp. at 13.) According to plaintiff, because the  
16 Article was directed to a limited portion of the public and the Article was not published in the  
17 context of any ongoing medical controversy or debate, there can be no constitutionally protected  
18 activity. (Opp. at 14.) Plaintiff cites to *DuCharme v. International Broth. of Elec. Workers*,  
19 *Local 45*, 110 Cal. App.4th 107, 119 (2003).

20 In *DuCharme*, a union posted information on its website that plaintiff had been removed  
21 from office for financial mismanagement. The court found that the issue was of interest to only a  
22 limited but definable portion of the public:

23 in order to satisfy the public issue/issue of public interest requirement of section  
24 425.16, subdivision (e)(3) and (4) of the anti-SLAPP statute, in cases where the  
25 issue is not of interest to the public at large, but rather to a limited, but definable  
26 portion of the public (a private group, organization, or community), the  
27 constitutionally protected activity must, at a minimum, occur in the context of an  
ongoing controversy, dispute or discussion, such that it warrants protection by a  
statute that embodies the public policy of encouraging participation in matters of  
public significance.

28 *Id.*

1 The court highlighted that the posting on the union website merely reported on the fact of  
2 DeCharme’s termination. As a result, members of the local union “were not being urged to take  
3 any position on the matter. . . . To grant protection to mere informational statement, in this  
4 context, would in no way further the statute’s purpose of encouraging participation in matters of  
5 public significance.” *Id.* at 118. Thus, because the notification of plaintiff’s termination was a  
6 “fait accompli”, there could be no furthering of participation. *Id.*

7 The AACC is an “international scientific/medical society of clinical laboratory  
8 professionals, physicians, research scientists and other individuals involved with clinical  
9 chemistry and related disciplines,” with over 8,000 members. (AACC Mtn to Strike, Exh.1.)  
10 Although the various published CLINICAL CHEMISTRY articles are available to the general  
11 public by way of the AACC website, they are not directed to the general public but to a small,  
12 definable portion of the population. The Court finds that § 425.16(e)(4) more readily fits the  
13 current situation described in *DuCharme*. Therefore, even if the Article was not of interest to the  
14 public at large, it occurred in the context of an ongoing controversy, dispute or discussion that  
15 encouraged participation in an issue of public significance, *i.e.*, the use of an ST2 biomarker for  
16 screening cardiovascular disease in asymptomatic people.

17 Plaintiff points to some articles that have discussed its ST2 Assay, but there has been no  
18 ST2 assay approved by FDA for use with the nonsymptomatic patient and there is no uniformity  
19 in the literature about ST2 as a biomarker for population screening, which demonstrates that the  
20 issue requires further research and development. The Article was not providing mere undisputed,  
21 fixed information about ST2 assays in general, but reported scientific conclusions based on a  
22 particular study, and invited additional research and study of a public issue or a matter of public  
23 significance.

24 Accordingly, defendants have met their burden of showing that the allegedly defamatory  
25 statements in the Article were “in furtherance of the exercise of the constitutional right of  
26 petition or the constitutional right of free speech in connection with a public issue or an issue of  
27 public interest” and were published in the context of any ongoing controversy or debate.

28 ///

1 **2. Reasonable Probability of Prevailing on the Merits**

2 Because defendants have made the threshold showing that the challenged causes of  
3 action, libel per se, libel per quod and trade libel, arise from a protected activity, plaintiff must  
4 establish a probability of prevailing on the claims alleged. Defamation requires that the allegedly  
5 false statements be unprivileged. CAL. CIV. CODE § 45 (“Libel is a false and *unprivileged*  
6 publication . . . which has a tendency to injure him in his occupation.”). Section 47 “extends a  
7 conditional privilege against defamation to statements made without malice on subjects of  
8 mutual interests.” *Hui v. Sturbaum*, 166 Cal. Rptr.3d 569, 577 (Cal. App. 2014). The existence  
9 of the conditional privilege against defamation is ordinarily a question of law for the court. CAL.  
10 CIV. CODE § 47. Defendants contend that the common interest privilege applies in this situation.

11 The conditional privilege against defamation to statements made without malice on  
12 subjects of mutual interests is “recognized where the communicator and the recipient have a  
13 common interest and the communication is of a kind reasonably calculated to protect or further  
14 that interest.” *Hawran v. Hixson*, 209 Cal. App.4th 256, 287 (2012). The “interest” is restricted  
15 to “proprietary or narrow private interests.” *Id.*

16 Defendants correctly note that scholarly activity generally fits within the common interest  
17 privilege. *See Harkonen v Fleming*, 880 F. Supp.2d 1071, 1079 (N.D. Cal. 2012), citing *Taus v.*  
18 *Loftus*, 40 Cal. 4th 683, 721 (2007). In both *Harkonen* and *Taus*, the courts found the common  
19 interest privilege applicable and accordingly did not delve into “whether the statements were  
20 capable of defamatory meaning or if they were constitutionally protected opinion instead of  
21 fact.” Ameet Kaur Nagra, Note, *A Higher Protection for Scholars Faced with Defamation Suits*,  
22 41 HASTINGS CONST. L.Q., 175, 200 (2013). “In deciding whether the privilege applied – instead  
23 of attempting to discern defamatory meaning – the court in both cases considered the context in  
24 which the statements were made and the purpose and identity of the individuals that produced  
25 them.” *Id.* at 201.

26 In the present case, it is beyond dispute that the author defendants conducted serious and  
27 rigorous research that was peer-reviewed prior to publication in a well-respected scientific  
28 journal. As noted above and conceded by plaintiff, the Article was directed to an interested



1 audience and not to the general population. The author defendants, through the publisher of the  
2 scholarly journal and the editor of the journal, presented their findings to an audience that shared  
3 their scholarly interests and activities. Accordingly, defendants have established that the  
4 statements at issue are privileged.

5       Because the statements fall within the common interest privilege, plaintiff now bears the  
6 burden of showing the statements were made with malice. The malice necessary to defeat the  
7 qualified common interest privilege is actual malice. *Hui*, 166 Cal. Rptr.3d at 579. In *Agarwal*,  
8 the California Supreme Court stated that “[t]he malice referred to by the statute is actual malice  
9 or malice in fact, that is, a state of mind arising from hatred or ill will, evidencing a willingness  
10 to vex, annoy or injure another person.” *Agarwal v. Johnson*, 25 Cal.3d 932, 944 (1979). There  
11 is, however, an alternative method of showing malice: defendant lacked reasonable grounds for  
12 belief in the truth of the publication and therefore acted in reckless disregard of the plaintiff’s  
13 rights. *Sanborn v. Chronicle Pub. Co.*, 18 Cal.3d 406, 413 (1976); *see also Noel v. River Hills*  
14 *Wilsons, Inc.*, 113 Cal. App.4th 1363, 1370 (2003). “In demonstrating reckless disregard, it is  
15 not sufficient that the statements are shown to be inaccurate, or even unreasonable.” *Glenn K.*  
16 *Jackson, Inc. v. Rose* 273 F.3d 1192, 1202 (9th Cir. 2011). Instead, “[o]nly willful falsity or  
17 recklessness will suffice.” *Id.*, quoting *Cabanas v. Gloodt Assocs.*, 942 F.Supp. 1295, 1301 n. 7  
18 (E.D. Cal.1996); *see also Rogers v. Home Shopping Network, Inc.*, 73 F. Supp.2d 1140 (C.D.Cal.  
19 1999)(a libel plaintiff must establish that the defendant realized that his statement was false or  
20 that he subjectively entertained serious doubt as to the truth of his statement). Mere negligence  
21 does not provide a showing of lack of reasonable grounds. Malice is shown only when the  
22 negligence amounts to a reckless or wanton disregard for the truth, so as to imply a willful  
23 disregard for, or avoidance of, accuracy. *Noel v. River Hills Wilsons, Inc.*, 113 Cal. App.4th  
24 1363, 1370-71 (2003).

25       Plaintiff has failed to provide any evidence establishing that any defendant possessed a  
26 state of mind arising from hatred or ill will toward plaintiff or plaintiff’s Presage ST2 Assay.  
27 Nor has plaintiff presented evidence that defendants knew the statements plaintiff refers to as  
28 defamatory were false or that even if negligently made, defendants acted with reckless or wanton

1 disregard for the truth. As a result, plaintiff’s defamation claims must be stricken under  
2 California Code of Civil Procedure § 425.16

3 **c. Trade Libel**

4 Although the common interest privilege appears to be applicable to a cause of action for  
5 trade libel much like libel per se and libel per quod, there is an additional factor that prevents  
6 this cause of action from going forward in this action under the anti-SLAPP statute.

7 “Trade libel is defined as an intentional disparagement of the quality of property, which  
8 results in pecuniary damage to plaintiff.... “Injurious falsehood, or disparagement, then, may  
9 consist of the publication of matter derogatory to the plaintiff’s title to his property, or its quality,  
10 or to his business in general, ... [T]he plaintiff must prove in all cases [that the publication has  
11 played a material and substantial part inducing others not to deal with him, and that as a result he  
12 has suffered special damages.... Usually, ... the damages claimed have consisted of loss of  
13 prospective contracts with the plaintiff’s customers.” *Nichols v. Great American Ins. Companies*,  
14 169 Cal. App.3d 766, 773 (1985); *see also Leonardini v. Shell Oil Co.*, 216 Cal. App.3d 547,  
15 572 (1989). To constitute trade libel, a statement must be false. *Id.*; *see also Polygram Records*,  
16 *Inc. v. Superior Court*, 170 Cal. App.3d 543, 548 (1985).

17 Further, a claim based on trade libel “must specifically refer to, or be ‘of and concerning,’  
18 the plaintiff in some way.” *Blatty v. New York Times Co.* 42 Cal.3d 1033, 1042 (1986), cert. den.  
19 485 U.S. 934 (1988).

20 The “of and concerning” or specific reference requirement limits the right of action  
21 for injurious falsehood, granting it to those who are the direct object of criticism  
22 and denying it to those who merely complain of nonspecific statements that they  
23 believe cause them some hurt. To allow a plaintiff who is not identified, either  
*Id.* at 1044.

24 Plaintiff contends that the statements it identified from the Article are disparaging or  
25 would persuade a consumer to avoid its product. But the study at the center of the Article did not  
26 involve research of an assay or assays in assessing the prognosis of patients already diagnosed  
27 with chronic heart failure – the precise clinical use of plaintiff’s FDA approved Presage ST2  
28 assay. Any use of plaintiff’s ST2 assay would have been an off-label use. Accordingly, the

1 statements in the Article do not and could not discourage the purchase of plaintiff’s product for  
2 its FDA-approved use. In other words, the statements do not specifically refer to or concern the  
3 plaintiff or plaintiff’s product in some way.

4 Plaintiff’s claim for trade libel is neither legally sufficient nor supported by a sufficient  
5 prima facie showing of facts to sustain a favorable judgment if the evidence submitted by the  
6 plaintiff is credited. Because plaintiff has not established a probability of prevailing on the trade  
7 libel claim, it will be stricken under § 425.16.

8 **d. California Business and Professions Code §17200, et seq**

9 Plaintiff alleges in its unfair competition law (“UCL”) cause of action that defendants’  
10 actions in publishing false statements about the Presage ST2 assay constitutes an unlawful,  
11 unfair, or fraudulent business practice and amounts to unfair competition. However, “California’s  
12 consumer protection laws, like the unfair competition law, govern only commercial speech . . .  
13 noncommercial speech is beyond their reach.” *Rezec v. Sony Pictures Entertainment, Inc.*, 116  
14 Cal. App.4th 135, 140 (2004). “Commercial speech” is usually defined as speech that does no  
15 more than propose a commercial transaction. *Bernando v. Planned Parenthood Federation of*  
16 *America*, 115 Cal. App.4th 322, 343 (2004).

17 “In typical commercial speech cases, the speaker is likely to be someone engaged in  
18 commerce—that is, generally, the production, distribution, or sale of goods or services—or  
19 someone acting on behalf of a person so engaged, and the intended audience is likely to be actual  
20 or potential buyers or customers of the speakers goods or services, or persons acting for actual or  
21 potential buyers or customers, or persons (such as reporters or reviewers) likely to repeat the  
22 message to or otherwise influence actual or potential buyers or customers....” *Rezec*, 116 Cal.  
23 App.4th at 140-41. “In short, commercial speech is speech that does ‘no more than propose a  
24 commercial transaction’” *Id.* at 141 [citations omitted].

25 Here, the Article at issue does not in any manner propose a commercial transaction in its  
26 content. Instead, it is provides a scholarly report of the results of a specific scientific study. For  
27 plaintiff to suggest otherwise is disingenuous. Accordingly, plaintiff has failed to show a  
28 reasonable probability of prevailing on its UCL claim because the Article is not commercial in

1 nature or that the intended audience of the Article was likely to be actual or potential customers  
2 of plaintiff or the Alere assay used in the study. As a result, dismissal of plaintiff's UCL claim  
3 under the anti-SLAPP statute is required.

4 **D. CONCLUSION**

5 The Court has determine that defendants AACC and Dr. Rafai have made a threshold  
6 showing that all of plaintiff's causes of action "arise from" a protected activity. Further, the  
7 Court finds and concludes that plaintiff has not established a probability of prevailing on the  
8 libel claims because of the applicability of the common interest privilege and plaintiff's failure  
9 to show malice, and on the UCL claim because the Article at issue it is not commercial speech.

10 Section 425.16(c) provides: "In any action subject to subdivision (b), a prevailing  
11 defendant on a special motion to strike shall be entitled to recover his or her attorney's fees and  
12 costs."

13 Based on the foregoing, **IT IS ORDERED:**

14 1. Defendant Rafai's motion to strike the complaint in its entirety is **GRANTED;**

15 2. Defendant AACC'S amended motion to strike the complaint in its entirety is  
16 **GRANTED;**

17 3. Defendants Rafai and AACC, as the prevailing defendant, are entitled to attorney's  
18 fees and costs. Defendants shall file their motions for attorney's fees and costs within 20 days of  
19 the filing of this Order. Counsel is advised to contact the chambers of the undersigned within  
20 three days of the filing of this Order so as to obtain a hearing date in conformity with the Civil  
21 Local Rules.

22 **IT IS SO ORDERED.**

23 DATED: February 18, 2014

24   
25 M. James Lorenz  
26 United States District Court Judge

27 COPY TO:

28 HON. MITCHELL D. DEMBIN  
UNITED STATES MAGISTRATE JUDGE  
ALL PARTIES/COUNSEL

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28